Brian A. Moser

1.3k total citations
24 papers, 935 citations indexed

About

Brian A. Moser is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Brian A. Moser has authored 24 papers receiving a total of 935 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 7 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Brian A. Moser's work include Antiplatelet Therapy and Cardiovascular Diseases (10 papers), Lipoproteins and Cardiovascular Health (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Brian A. Moser is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (10 papers), Lipoproteins and Cardiovascular Health (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Brian A. Moser collaborates with scholars based in United States, Sweden and Netherlands. Brian A. Moser's co-authors include Joseph A. Jakubowski, Dominick J. Angiolillo, Kevin L. Duffin, Philippe Zaoui, James R. Voelker, Yoram Yagil, Matthew J. Sheetz, Tong Shen, Julia B. Lewis and Paul H. Berg and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Neurology.

In The Last Decade

Brian A. Moser

24 papers receiving 915 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian A. Moser United States	14	419	242	195	131	114	24	935
Akira Shouzu Japan	21	423 1.0×	217 0.9×	597 3.1×	184 1.4×	147 1.3×	34	1.3k
RosaMaria Marfisi Italy	13	374 0.9×	130 0.5×	323 1.7×	170 1.3×	39 0.3×	17	1.2k
Axel Åkerblom Sweden	17	745 1.8×	323 1.3×	122 0.6×	143 1.1×	29 0.3×	42	1.1k
Cesare Alessandri Italy	17	175 0.4×	313 1.3×	100 0.5×	155 1.2×	71 0.6×	29	1.1k
Keisuke Kohno Japan	18	425 1.0×	516 2.1×	142 0.7×	151 1.2×	114 1.0×	30	1.3k
Anders Bröijersén Sweden	15	289 0.7×	212 0.9×	121 0.6×	124 0.9×	58 0.5×	27	719
Arihiro Kiyosue Japan	19	274 0.7×	486 2.0×	377 1.9×	507 3.9×	38 0.3×	72	1.2k
H Sinzinger Austria	14	189 0.5×	201 0.8×	112 0.6×	74 0.6×	91 0.8×	144	783
Zhaoqing Wang United States	17	906 2.2×	245 1.0×	391 2.0×	137 1.0×	522 4.6×	46	2.1k
Adriana Branchi Italy	14	173 0.4×	296 1.2×	155 0.8×	361 2.8×	53 0.5×	40	1000

Countries citing papers authored by Brian A. Moser

Since Specialization

Citations

This map shows the geographic impact of Brian A. Moser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Moser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Moser more than expected).

Fields of papers citing papers by Brian A. Moser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian A. Moser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Moser. The network helps show where Brian A. Moser may publish in the future.

Co-authorship network of co-authors of Brian A. Moser

This figure shows the co-authorship network connecting the top 25 collaborators of Brian A. Moser. A scholar is included among the top collaborators of Brian A. Moser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian A. Moser. Brian A. Moser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Silverberg, Jonathan I., Thomas Bieber, Kilian Eyerich, et al.. (2024). 732 - EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations. British Journal of Dermatology. 191(Supplement_2). 1 indexed citations

Martinez, James M., Nada Hindiyeh, Greg Anglin, et al.. (2020). Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine. Cephalalgia. 40(9). 978–989. 9 indexed citations

Harding, James J., Andrew X. Zhu, Todd M. Bauer, et al.. (2019). A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research. 25(17). 5202–5211. 32 indexed citations

Martinez, James M., Nada Hindiyeh, Greg Anglin, et al.. (2019). Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine (P1.10-017). Neurology. 92(15_supplement). 2 indexed citations

Moser, Brian A., Elizabeth LaBell, Emmanuel Chigutsa, Joseph A. Jakubowski, & David S. Small. (2017). Population Pharmacokinetic and Exposure–Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia. Clinical Pharmacokinetics. 57(2). 243–254. 4 indexed citations

Bendell, Johanna C., Charles S. Fuchs, Martin H. Voss, et al.. (2017). Abstract CT090: A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors. Cancer Research. 77(13_Supplement). CT090–CT090. 1 indexed citations

Voelker, James R., Paul H. Berg, Matthew J. Sheetz, et al.. (2016). Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. Journal of the American Society of Nephrology. 28(3). 953–962. 213 indexed citations

Rosen, Lee S., Jonathan W. Goldman, Alain P. Algazi, et al.. (2016). A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. Clinical Cancer Research. 23(8). 1910–1919. 57 indexed citations

Azaro, Analía, Jordi Rodón, Antonio Calles, et al.. (2015). A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational New Drugs. 33(3). 710–719. 25 indexed citations

10.

Banck, Michaela S., Rashmi Chugh, Ronald B. Natale, et al.. (2015). Abstract A55: Phase 1 results of emibetuzumab (LY2875358), a bivalent MET antibody, in patients with advanced castration-resistant prostate cancer, and MET positive renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma. Molecular Cancer Therapeutics. 14(12_Supplement_2). A55–A55. 6 indexed citations

11.

Styles, Lori, Darell Heiselman, Brian A. Moser, et al.. (2014). Prasugrel in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology. 37(1). 1–9. 20 indexed citations

12.

Bergmeijer, Thomas O., Udaya S. Tantry, Jurriën M. ten Berg, et al.. (2014). The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thrombosis and Haemostasis. 112(9). 589–597. 24 indexed citations

13.

Jakubowski, Joseph A., Dominick J. Angiolillo, Chunmei Zhou, et al.. (2014). The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study. Thrombosis Research. 134(3). 552–557. 17 indexed citations

14.

Angiolillo, Dominick J., Joseph A. Jakubowski, José Luis Ferreiro, et al.. (2014). Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease. Journal of the American College of Cardiology. 64(10). 1005–1014. 134 indexed citations

15.

James, Stefan, Suman Duvvuru, Joseph A. Jakubowski, et al.. (2014). Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thrombosis and Haemostasis. 112(5). 943–950. 13 indexed citations

16.

Erlinge, David, Paul A. Gurbel, Stefan James, et al.. (2013). Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients. Journal of the American College of Cardiology. 62(7). 577–583. 64 indexed citations

17.

Erlinge, David, Jurriën M. ten Berg, David P. Foley, et al.. (2012). Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients. Journal of the American College of Cardiology. 60(20). 2032–2040. 63 indexed citations

18.

Erlinge, David, Stefan James, Suman Duvvuru, et al.. (2012). TCT-725 Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology. 60(17). B211–B212. 1 indexed citations

19.

Turner, P. Kellie, Brian A. Moser, Jay Tuttle, & Volker Wacheck. (2012). Adapting a Target-mediated Drug Disposition (TMDD) Model to Account for Delayed t max Following IV Infusion of a Monoclonal Antibody. 1 indexed citations

20.

Man, Michael, Mark W. Farmen, Carmen M. Dumaual, et al.. (2010). Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans. The Journal of Clinical Pharmacology. 50(8). 929–940. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact